Finanzen von BridgeBio Oncology Therapeutics Inc (BBOT)BBOTBridgeBio Oncology Therapeutics Inc

Evaluating the bottom line, BridgeBio Oncology Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -381.87%, provide a clear picture of how effectively BBOT converts its operational activities into shareholder value.

In the context of the broader market, BBOT competes directly with industry leaders such as ALLO and STTK. With a market capitalization of $736.00M, it holds a leading position in the sector. When comparing efficiency, BBOT's gross margin of N/A stands against ALLO's 100.00% and STTK's N/A. Such benchmarking helps identify whether BridgeBio Oncology Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has reported increasing net losses, with the latest quarter showing a net income loss of $56.45 million. The EPS has been negative, with the most recent reported EPS at -0.71.